iStock_000089128027_Large.jpg
 
 

Nonagen Bioscience Announces Results from a Meta-Analysis of Studies with Oncuria™

  • Jan 3, 2018

Oncuria™ predicts the presence of bladder cancer in a simple urine sample.  

JACKSONVILLE, FLY, Jan 3, 2018 – Nonagen Bioscience today announced that new data from a meta-analysis of clinical studies comprised of > 1,100 patients showed that a 10-plex urine-based bladder cancer diagnostic signature has the potential to non-invasively predict the presence of bladder cancer in at-risk patients (blood in the urine, hematuria, or a history of bladder cancer on surveillance). The study entitled "Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer" was reported in the January issue of Oncotarget 2018 Jan 3;9(6):7101-7111.

Oncuria™ measures expression levels of ten biomarkers that are then combined into a single score. The ten biomarkers measured by Oncuria™ are: APOE, A1AT, ANG, CA9, IL8, MMP9, MMP10, PAI1, SDC1 andVEGF.

Charles J. Rosser, MD, MBA, CEO, Nonagen Bioscience noted “Importantly, this analysis confirms the consistency and robustness of our previous findings, substantiate our US and Chinese patents and gives great anticipation to our ongoing Phase III clinical trials in the US. This is a very exciting time for Nonagen.”

State Intellectual Property Office of the People's Republic of China Grants Patent for multiplex bladder cancer signature

  • December 19, 2017

JACKSONVILLE, FL, Feb 3, 2016 – Nonagen Bioscience today announced that the State Intellectual Property Office of the People's Republic of China has issued certificate of issue patent No. 201380048105.8. The patent provides intellectual property protection for Nonagen Bioscience's Oncuria™ bladder cancer testing. 

Oncuria™ is an advanced urine test for adults with blood in the urine (hematuria) or a history of bladder cancer on surveillance and helps physicians determine risk of patient harboring bladder cancer. Oncuria™ measures expression levels of ten biomarkers that are then combined into a single score. The ten biomarkers measured by Oncuria™ are: APOE, A1AT, ANG, CA9, IL8, MMP9, MMP10, PAI1, SDC1 andVEGF.

The recently issued patent is co-assigned to Nonagen Bioscience and Drs. Charles J. Rosser and Steve Goodison and is the first patent issued relating to Oncuria™. Nonagen will continue to pursue additional patent applications, which if issued, should expand the scope of intellectual property protection for Oncuria™.

 

United States Patent and Trademark Office Grants Patent for multiplex bladder cancer signature

  • February 3, 2016

JACKSONVILLE, FL, Feb 3, 2016 – Nonagen Bioscience today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,249,467. The patent, which is expected to expire in 2031, provides intellectual property protection for Nonagen Bioscience's Oncuria™ bladder cancer testing. 

Oncuria™ is an advanced urine test for adults with blood in the urine (hematuria) or a history of bladder cancer on surveillance and helps physicians determine risk of patient harboring bladder cancer. Oncuria™ measures expression levels of ten biomarkers that are then combined into a single score. The ten biomarkers measured by Oncuria™ are: APOE, A1AT, ANG, CA9, IL8, MMP9, MMP10, PAI1, SDC1 andVEGF.

The recently issued patent is co-assigned to Nonagen Bioscience and Drs. Charles J. Rosser and Steve Goodison and is the first patent issued relating to Oncuria™. Nonagen will continue to pursue additional patent applications, which if issued, should expand the scope of intellectual property protection for Oncuria™.